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Abstract
Background: Hepatitis B virus (HBV) is still one of the serious infectious risks for the blood transfusion safety in
China. One plausible reason is the emergence of the variants in the major antigenic alpha determinant within the
major hydrophilic region (MHR) of hepatitis B surface antigen (HBsAg), which have been assumed to evade the
immune surveillance and pose a challenge to the disease diagnosis. It is well documented that some commercial
ELISA kits could detect the wild-type but not the mutant viruses. The high prevalence of HBV in China also
impaired the application of nucleic acid testing (NAT) in the improvement of blood security. Molecular
epidemiological study of HBsAg variations in China is still limited. This study was designed to identify the
prevalence of mutations in the HBsAg in voluntary blood donors in Nanjing, China.
Methods: A total of 20,326 blood units were enrolled in this study, 39 donors were positive for HBV S gene in the
nested-PCR. Mutations in the major hydrophilic region (MHR; aa 99-169) were identified by direct sequencing of S
region.
Results: Among of 20,326 blood units in the Red Cross Transfusion Center of Nanjing from October 2008 to April
2009, 296 samples (1.46%, 296/20,326) were HBsAg positive in the 2 successive rounds of the ELISA test. In these
HBsAg positive units, HBV S gene could be successfully amplified from 39 donors (13.18%, 39/296) in the nested-
PCR. Sequence analysis revealed that 32 strains (82.1%, 32/39) belong to genotype B, 7 strains (17.9%, 7/39) to
genotype C. Besides well known G145R, widely dispersed variations in the MHR of S region, were observed in 20
samples of all the strains sequenced.
Conclusions: HBV/B and HBV/C are dominant in Nanjing, China. The mutations in the MHR of HBsAg associated
with disease diagnosis are common.
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Introduction
Hepatitis B is a major global health problem and the most
serious type of viral hepatitis, leading to the liver cirrhosis
and liver cancer in the chronic consequences. Worldwide,
it is estimated that more than 2 billion people have been
infected with Hepatitis B virus (HBV), one-third reside in
China [1]. Over the last 20 years, although the vaccination
program has contributed to a reduction in HBV infection,
decreasing from nearly 10% to approximately 7% in the
general population [2], China is still an intermediate/high
endemic country for hepatitis [3,4].
H B Vi ss t i l lo n eo ft h es e r i o u si n f e c t i o u sr i s k sf o rt h e
blood transfusion safety in China [5-8]. One plausible
reason is the emergence of the variants in the major anti-
genic alpha determinant of hepatitis B surface antigen
(HBsAg) [9-17], which have been assumed to evade the
immune surveillance and pose a challenge to the disease
diagnosis [18-21]. It is well documented that some com-
mercial ELISA kits could detect the wild-type but not the
mutant viruses [5,22]. HBV nucleic acid testing (NAT)
are introduced as a mandatory test for the blood supply
to reduce such a risk in some developed countries
[23-28]. The high prevalence of HBV in China, however,
impaired the application of NAT in the improvement of
blood security. Moreover, HBV NAT is procedurally
cumbersome and incurs high costs [29].
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HBsAg has been adopted and observed strictly by blood
centers to reduce the risk of HBV transmission through
blood transfusion. Before the donation in the street, all of
the volunteers were asked for a fast colloidal gold assay for
HBsAg. Only the HBsAg negative volunteers were
accepted for blood donation. And the blood units in the
centers were further monitored for HBsAg with 2 succes-
sive rounds of the commercial ELISA kits. Few blood
units, if positive in either or both ELISA test, which is
more sensitive than the fast colloidal gold assay, would be
discarded. However, it could not rule out that ELISA occa-
sionally fails to detect HBV-infected donors, partially due
to the variants of HBsAg, especially the alpha determinant
region located at aa124-aa147 within the major hydrophi-
lic region (MHR) from aa99 to aa169 [30,31].
Variants of HBsAg in China have been reported else-
where. The alpha determinant mutation seemed to be
uncommon in community-based population of Shandong
province and the mutation sites were relatively scattered
[32]. G145R was the major variation in the HBV isolates
responsible for the occult HBV infections in Xiamen,
China [33]. In the blood donors with occult HBV infection
( O B I )i nN a n j i n g ,m u t a t i o nw a so b s e r v e di nt h ea l p h a
determinant of HBsAg from only 1 of 5 samples [34].
However, the samples enrolled in those experiments were
rather limited. And more importantly, the blood donors
with OBI, which is defined as the ‘presence of HBV DNA
in the liver of individuals testing HBsAg-negative with cur-
rently available assays’ [35], is different from the blood
donors with HBsAg positive enrolled in this study. Here,
we have analyzed HBV genotype/serotype and mutations
in MHR of HBsAg from 39 HBV S gene positive samples
from 20,326 voluntary blood donors in Nanjing, which is
the capital of Jiangsu Province and the home for over 8
million people.
Methods
Samples
From October 2008 to April 2009, a total of 20,326 blood
units were collected by the Red Cross Transfusion Center
of Nanjing. The subjects in the study ranged from 20 to
55 years old (mean ± SD; 32.3 ± 10.5), with 10,690 males
(52.5%) and 9,636 females (47.4%). All of the samples were
HBsAg negative upon a commercial colloidal gold immu-
nochromatography assay (InTec Ltd, Xiamen, China)
before the blood donation in the street. Approval from the
local institutional ethics committee was obtained before
the study.
HBV ELISA
The blood units in the center were further detected for
HBsAg with two different commercial ELISA kits, from
InTec Ltd, Xiamen and KHB Ltd, Shanghai. All assays
were performed according to the manufacturer’s instruc-
tions. Blood samples were separated and stored at -70°C
until use.
Sequencing of the S gene
All samples that were HBsAg-positive by either ELISA
were subjected to nested PCR targeting the S gene. Viral
DNA was extracted from 400 ul of plasma using a
QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Ger-
many). The first round of PCR was performed using an
outer primer set (5’- ACTGTCTCTGCCATATCGTCA-
3’,5 ’-CCAACACCCAATTACATATC-3’) for 30 cycles
(94°C for 30 s, 56°C for 30 s, and 72°C for 40 s). The
second round was performed using an inner primer set
(5’- ATGGAGAACATCGCATCAGG-3’,5 ’-TTAAATG-
TATACCCAAAGAC-3’) for 35 cycles (94°C for 30 s,
58°C for 30 s, and 72°C for 30 s). PCR products were
sequenced directly on an ABI Prism 3130X automatic
genetic analyzer (Invitrogen, Shanghai).
Results
HBV prevalence in the blood donors
Among of 20,326 blood units, 296 samples (1.46%, 296/
20,326) were HBsAg positive in the 2 successive rounds of
the ELISA test, with 189 males( 6 3 . 9 % )a n d1 0 7f e m a l e s
(36.1%). There were 10 samples positive for InTec Ltd
only, 9 samples positive for KHB Ltd only, and 277 sam-
ples positive for both. In these 296 HBsAg positive units,
HBV S gene could be successfully amplified from 39
donors (13.18%, 39/296). Sample 502019, 509344 and
573590 were negative for InTec ELISA but positive for
KHB ELISA, sample 506591 was positive for InTec ELISA
but negative for KHB ELISA. Table 1 summarizes the
ELISA results of these 39 donors.
HBV genotypes and serotypes
Phylogenetic analysis of the S gene sequences of the 39
cases indicated that 32 strains (82.1%, 32/39) belonged to
genotype B, 7 strains (17.9%, 7/39) to genotype C. No
other genotypes were observed. To define the subgentoype
of HBV, reference strains of B1 ~ B6 and C1 ~ C4
retrieved from Genebank were also included in the analy-
sis. Among of strains from genotype B, 28 strains (87.5%)
were from B2, 3 strains from B1, only 1 strain (564014)
was from B4. Seven strains from genotype C were divided
into four C1 and three C2 (Figure 1).
In the genotype B group, 29 sequences belonged to
serotype adw2 (122 K + 160 K + 127P), samples 564014
and 560744 were from ayw1 (122R + 160 K + 127P +
159A), but the sample 522082 (122 K + 160 K + 127H)
could not be classified into serotype adw2, adw3 or
adw4 for the mutation P127H. Seven strains from
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+ 160R + 177 V) and two adrq- (122 K + 160R + 177A)
(Figures 2 and 3).
Mutations in MHR of HBsAg
To explore the mutations affecting the antigenicity of
HBsAg, MHR within the major antigenic alpha determi-
nant were analyzed. In 32 sequences of genotype B cases,
there were 21 samples (65.6%, 21/32) with multiple muta-
tions in the major hydrophilic region. The well-known
G145R substitution was found in the 5 sequences, i.e.,
531355, 546227, 563060, 506519, 525706, all of which
were from B2/adw2. Besides G145R, there were different
types of aa substitutions in the MHR that were associated
with lower reactivity in HBsAg assays reported in previous
studies: i.e. D99N, Q101R/H, L109I, I110N, T115S, S117T,
P120S, K122R, S126T/A, P127H, A128V, Q129R/H/L,
G130E, T131N/A, M133T/L/S, F134R/I/L, T143M,
A159V, F161Y, W163G, E164G, V168A. In the sequences
502019 and 565200, mutations were clustered before but
not within the MHR: L91S, I92P, F93C/G, L94W, L95R,
Table 1 The ELISA results of 39 HBV S gene DNA positive
donors
sample InTec KHB sample InTec KHB sample InTec KHB
502019
# 0.047 0.138 522801 1.885 1.285 561451 2.542 9.991
502800 9.993 9.998 525706 0.387 0.517 563060 1.653 1.309
505194 9.994 9.994 526765 0.107 0.082 564014 2.928 9.985
506519
& 0.18 0.01 530119 1.288 1.103 565200 1.103 1.303
506588 2.963 9.999 531355 2.498 2.711 565380 2.691 2.785
509344
# 0.027 2.111 531508 0.127 0.234 566102 0.114 0.12
510260 2.855 2.169 532014 2.456 1.743 572640 1.116 1.232
510351 9.991 9.993 534991 9.999 9.999 573590
# 0.001 2.827
513357 2.263 9.992 546227 0.272 0.26 574273 2.834 9.999
517437 0.052 0.088 549409 2.615 2.745 577612 10.001 9.992
518796 2.443 2.922 554464 0.235 0.426 578193 2.83 2.454
519821 0.258 0.627 560744 9.992 2.648 578265 0.316 0.538
522082 0.134 0.161 561321 2.807 9.993 579524 2.755 9.999
1. The cutoff value of was 0.105, which was calculated from the twice that of
mean OD of the negative control plus 0.005. The mean OD of the negative
control is taken as least as 0.050
2. # indicate the sample was positive for KHB ELISA only (502019, 509344 and
573590)
3. & indicate the sample was positive for InTec ELISA only (506591)
Figure 1 Phylogenetic analysis based on nucleotide sequencing of the small S region. The tree contains sequences from 39 samples and
a set of representative sequences belonging to genotypes and subgenotypes retrieved from Genebank. The phylogenetic tree was constructed
using the neighbor-joining method in ClustalW2.
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cases, mutations in the MHR could be found in all of the
samples, i.e. D99N, Y100F, Q101R/H, L110I, T113S,
S114T, S117T, T118M, I126T/V, W165L, and V168A,
which may be associated with antigenicity of HBsAg.
G145R substitution, however, was not observed. Similar
with sequences 502019 and 565200 from genotype B,
sequence 513357 from genotype C showed mutations
clustered before the MHR: L91S, I92P, F93C, L94W,
V96W, and L97F.
No mutation was observed with C residues at position
124, 137, 139, 147, or 149, which proved to play a critical
role in the conformational structure of the alpha determi-
nant in vitro studies. Phe at position 93 was replaced with
cysteine residue (F93C) in the sequence 502019 from gen-
otype B and sequence 513357 from genotype C.
Discussion
In the HBsAg screening test, whether NAT should be
incorporated into donor screening in China is still in
debate, although NAT could reduce the risk of HBV trans-
mission through blood donation. One of the reason is that
NAT is cubersmome. Thus, before the NAT incorporated
into donor screening in China, standard operation proce-
dures should be made and observed in the blood banks.
In China, the fast colloidal gold assay is the fist defence
line of blood safety in China. Compared with the fast col-
loidal gold assay, ELISA is more sensitive. And significant
few samples (1.46%, 296/20,326) were positive in the
ELSIA but negative in the street assay before the blood
donation. Two different commercial HBsAg kits from
InTec Ltd, Xiamen and KHB Ltd, Shanghai are widely
a p p l i e di nC h i n a .I ts h o u l db en o t e dt h a ts o m es a m p l e s
were only positive for one of them but not both, which
suggested that these two kits may be complementary. In
these 296 HBsAg positive units, HBV S gene could be suc-
cessfully amplified from 39 donors (13.18%, 39/296),
which confirmed the ELISA assay and proved that at least
these samples were contagious and should be discarded.
Indeed, all of the HBsAg positive samples were considered
to be dangerous and could not be used in the blood trans-
fusion. The failure of PCR targeting S gene in the majority
of HBsAg positive samples was more likely due to the low
virus load in these samples.
Figure 2 Multiple sequence alignment with hierarchical clustering based on the protein sequences of the MHR of HBsAg from
genotype B. Yellow shaded area indicated the MHR (aa99-aa169), Red shaded area indicated the alpha determinant region (aa124-aa147).
Sample 506519 and 502019 was HBsAg negative in one of the kit from KHB Ltd or InTec Ltd.
Figure 3 Multiple sequence alignment with hierarchical clustering based on the protein sequences of the MHR of HBsAg from
genotype C. Yellow shaded area indicated the MHR (aa99-aa169), Red shaded area indicated the alpha determinant region (aa124-aa147).
Sample 573590 and 509344 was HBsAg negative in one of the kit from KHB Ltd or InTec Ltd.
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have been reported. In Shenyang, the largest city in the
northeast of China, HBV/C was widely distributed (50%)
in chronic patients or asymptomatic carriers along with
HBV/B (22%) and HBV/D (28%) [36]. In Xian from the
northwest region of China, 11 strains from blood donors
were clustered into genotype B and C [30]. In Guangzhou,
the largest city in southern China, 6/7 of occult HBV
infection (OBI) strains from blood donors were from
HBV/C [37]. In Qidong, the most eastern city in China, all
of the virus isolates from 81 vaccinated young adults with
OBI were also genotype C [38]. Compared with Guangz-
hou and Qidong, all of five blood donors with OBI in
Nanjing were infected with HBV/B [34]. Consistent with
the findings in the blood donors with OBI in Nanjing [34],
the present study demonstrates that HBV/B is also domi-
nant (82.1%, 32/39) in the blood donors with HBsAg posi-
tive in Nanjing.
Given the diversity of HBV genotypes [39], the classifica-
tion of a novel HBsAg amino acid change as a mutant
should be contingent on a substantial alteration in viral
function, such as antigenicity, infectivity, replication, and
morphology, which is attributable to the specific change.
The major hydrophilic region (MHR) extending from aa99
to aa169 clustered with a highly conformational epitope is
critical to the antigenicity of HBsAg [30,31]. Thus, amino
acid substitution in the MHR, either from variants in nat-
ural isolates or mutants under immunological pressure,
could cause the mistaken diagnosis of HBV in the HBsAg
screening test.
Amino acid changes of HBsAg in China have been
reported elsewhere, focusing on the chronic carrier [11],
OBI patients [33,34], vaccinated people [40]. The variants
of HBV on the general population in China [32], however,
remain elusive. In Shandong province, the alpha determi-
nant variation seemed to be uncommon (14.7%, 15/102)
in the community-based population and the mutation
sites were relatively scattered [32]. In the present study,
the variations with the alpha determinant aa124-aa147
were usual. In the 32 strains from genotype B, aa substitu-
tions could be observed in 16 sequences; in the 7 HBV/C
strains, variations could be identified in 4 sequences.
Totally, the mutation ratio was over 50% (51.3%, 20/39),
which was much higher than in Shandong Province,
reflecting the more widely application of HBV vaccine in
Nanjing [19].
The well-known G145R was the major variation in the
HBV isolates responsible for the occult HBV infections in
Xiamen, China [33]. G145R also has a direct impact on
the diagnosis [41]. Here, G145R could be identified in
5 samples, i.e., 531355, 546227, 563060, 506519, 525706.
Among of them, 506519 was negative in the HBsAg
ELISA kit from KHB Ltd, Shanghai, but positive in the kit
from InTec Ltd, Xiamen. Ther e m a i n i n gf o u rs a m p l e s
(531355, 546227, 563060 and 525706) were positive for
either of two kits. Since the mutation pattern in the MHR
of 531355, 546227 and 563060 was very similar with
506519, variation outside of MHR may also play important
roles for the loss binding of 506519 in the HBsAg ELISA
kit from KHB Ltd. Sample 509344 was negative in the
HBsAg ELISA kit from InTec Ltd, Xiamen. However, no
mutation could be identified within the MHR, further sug-
gesting the critical roles ofd o m a i n so u t s i d eo fM H Ri n
the antigenicity of HBsAg. Besides of G145R, different aa
substitutions within and outside of MHR were also found
in the samples from HBV/B and HBV/C. The effects of
these variations on the HBsAg and HBV warrants further
investment.
Conclusion
HBV/B and HBV/C are prevalent in the blood donors
with HBsAg positive, consistent with the previous find-
ing in the OBI patients in Nanjing. Mutations in the
MHR which may associate with HBsAg diagnosis are
common.
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